Related Experiment Video
Updated: Jun 3, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Neoadjuvant Targeted Therapy in Non-Small Cell Lung Cancer and Its Impact on Surgical Outcomes
Mark Sorin1,2, Caroline Huynh1,3, Merav Rokah3
1Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, Quebec, Canada.
Neoadjuvant targeted therapy for non-small cell lung cancer (NSCLC) shows potential but requires further study. This approach impacts surgical outcomes and the overall patient experience, highlighting the need for careful consideration in treatment planning.
Area of Science:
- Oncology
- Thoracic Surgery
- Pharmacology
Background:
- Limited evidence exists for neoadjuvant targeted therapy in non-small cell lung cancer (NSCLC).
- Currently, two phase 3 trials are recruiting, and no indications are approved for this treatment strategy.
Purpose of the Study:
- To describe clinical experience with neoadjuvant targeted therapy in operable non-small cell lung cancer (NSCLC).
- To highlight the importance of surgical outcomes as an underreported aspect of neoadjuvant therapy in NSCLC.
Main Methods:
- Retrospective review of patients with operable non-small cell lung cancer (NSCLC) who received neoadjuvant targeted therapy.
- Analysis of surgical outcomes, including potential benefits and risks associated with the therapy.
Main Results:
- Surgical outcomes are a critical, yet underreported, component of neoadjuvant targeted therapy for non-small cell lung cancer (NSCLC).
- The application of neoadjuvant targeted therapy presents both significant potential benefits and risks impacting surgical planning and execution.
Conclusions:
- Neoadjuvant targeted therapy significantly influences the patient experience in non-small cell lung cancer (NSCLC) treatment.
- The impact on surgical planning, strategy, and outcomes necessitates careful evaluation for optimal patient care.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...